Drug intelligence / Profile preview

clarithromycin + fluticasone

Development stage: Preclinical
Lead developer: Taisho Pharmaceutical
Modality: Small Molecules
Administration: Oral, Inhalation, Intranasal, Topical

Overview

This is a combination of clarithromycin, a macrolide antibiotic, and fluticasone, a synthetic glucocorticoid. While not marketed as a fixed combination product, these medications may be prescribed together in certain clinical scenarios. Clarithromycin has antibacterial, anti-inflammatory, and immunomodulatory effects, while fluticasone reduces inflammation. However, there is a significant drug interaction between these medications, as clarithromycin can increase fluticasone blood levels by inhibiting its metabolism.

Targets

GR (Glucocorticoid receptor)Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on clarithromycin + fluticasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clarithromycin + fluticasone.

Explore the full profile